Collaboration and License Agreement between ADC Therapeutics Sarl and Genmab A/SCollaboration and License Agreement • April 24th, 2020 • ADC Therapeutics SA • Pharmaceutical preparations • New York
Contract Type FiledApril 24th, 2020 Company Industry JurisdictionThis Collaboration and License Agreement (“Agreement”) is made and entered into, effective as of 14 June 2013 (“Effective Date”), by and between ADC Therapeutics Sarl, a Swiss corporation, having its head office at Rue Saint-Pierre 2, Lausanne, 1003, Switzerland (“ADCT”), and Genmab A/S, a Danish corporation, having its principal place of business at [**] (“Genmab”). Genmab and ADCT are sometimes referred to herein individually as a “Party” and collectively as the “Parties.”
Collaboration and License Agreement between ADC Therapeutics Sarl and Genmab A/SCollaboration and License Agreement • March 2nd, 2020 • ADC Therapeutics SA • Pharmaceutical preparations • New York
Contract Type FiledMarch 2nd, 2020 Company Industry JurisdictionThis Collaboration and License Agreement (“Agreement”) is made and entered into, effective as of 14 June 2013 (“Effective Date”), by and between ADC Therapeutics Sarl, a Swiss corporation, having its head office at Rue Saint-Pierre 2, Lausanne, 1003, Switzerland (“ADCT”), and Genmab A/S, a Danish corporation, having its principal place of business at [**] (“Genmab”). Genmab and ADCT are sometimes referred to herein individually as a “Party” and collectively as the “Parties.”
Collaboration and License Agreement between ADC Therapeutics Sarl and Genmab A/SCollaboration and License Agreement • September 6th, 2019 • ADC Therapeutics SA • Pharmaceutical preparations • New York
Contract Type FiledSeptember 6th, 2019 Company Industry JurisdictionThis Collaboration and License Agreement (“Agreement”) is made and entered into, effective as of 14 June 2013 (“Effective Date”), by and between ADC Therapeutics Sarl, a Swiss corporation, having its head office at Rue Saint-Pierre 2, Lausanne, 1003, Switzerland (“ADCT”), and Genmab A/S, a Danish corporation, having its principal place of business at [**] (“Genmab”). Genmab and ADCT are sometimes referred to herein individually as a “Party” and collectively as the “Parties.”